Pivotal (registrational) trial
The trial (usually a randomised phase 3, sometimes a large phase 2) whose results are submitted to regulators as the main evidence for approval. When a company calls a trial 'registrational' it is signalling that this is the one that decides.
Regulators traditionally required two adequate and well-controlled trials, but in oncology one pivotal trial with confirmatory supporting evidence is the norm. Pivotal trials define the approved population, dose and comparator, so their design is negotiated with the FDA in advance (end-of-phase-2 meetings, special protocol assessment). Phase 2 single-arm cohorts serve as pivotal for accelerated approval in rare or refractory diseases. A 'registration-directed' or 'registration-enabling' phase 2 signals a company's intent to file on it. Pivotal trials are the units this site's evidence and trial pages are built around.
Pages like this
not linked directly; found by shared links- TermComplete response letter (CRL)
Shares Confirmatory trial, BLA / NDA / MAA (marketing applications) and PDUFA dates.
- TermSurrogate endpoint
Shares Confirmatory trial, Primary, secondary and co-primary endpoints.
- TermObjective response rate (ORR)
Shares Single-arm trial, Primary, secondary and co-primary endpoints.